AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global charities supporting people with immune-mediated diseases. This multi-year collaboration aims to raise awareness and provide resources for autoimmune disease communities worldwide, leveraging Formula 1's global platform. The campaign will expand throughout the 2027 F1 season, combining motorsport excitement with AbbVie's commitment to medical innovation and patient support.
AbbVie shares are trading near their 52-week high of $285.42, currently priced at $285.24 with a modest 0.87% gain as of Oct 20, 2026 19:03 WIB on Pluang. The stock's dividend yield stands at 2.45%, while the market shows a higher inclination to sell with 72% of orders being sell orders compared to 28% buy orders. This trading activity contrasts with AbbVie's strong partnership announcement, highlighting investor caution despite the positive news.
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increase...
At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity...
AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
